Core Viewpoint - The Hong Kong stock market showed volatility on September 2, with the pharmaceutical sector leading gains, particularly the Hong Kong Stock Connect Medical ETF, which reached a new historical high [1] Group 1: Market Performance - The Hong Kong Stock Connect Medical ETF (159506) rose nearly 2%, achieving a new historical high [1] - Key constituent stocks such as BeiGene and 3SBio increased by over 4%, while WuXi AppTec and Kelun-Bio rose by over 2% [1] Group 2: Company Developments - Heng Rui Medicine announced that it received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554, which is the first EZH2 inhibitor developed in China [2][3] - The drug targets peripheral T-cell lymphoma (PTCL), which accounts for approximately 25%-30% of non-Hodgkin lymphoma patients in China, with a median onset age of 52 years [3] - Heng Rui's total R&D investment for SHR2554 has reached approximately 21.3 million yuan [3] Group 3: Future Outlook - The first half of 2025 is expected to see explosive growth in the export of Chinese innovative drugs, with significant increases in licensing-out transaction amounts [4] - The Chinese pharmaceutical industry is becoming a major source of global innovative drugs, contributing 50% of new drug molecules entering human clinical trials globally [4] - The Hong Kong Stock Connect Medical ETF focuses on capturing investment opportunities in the pharmaceutical sector, including medical devices, drugs, biotechnology, and medical services [4]

机构表示，港股医药板块经过近日大幅调整，风险稍有出清，本轮调整更多是短期波动，并不改行业长 期逻辑。近期政策端利好不断，国产创新药临床数据的不断积累，其在全球范围内的竞争力持续增强， 年内预计仍会有更多跨国BD交易，为行业带来新的增长动力。场外投资者亦可关注港股通医疗 ETF 富 国联接基金（联接 A：020110，联接 C：020111）。 今日港股医疗震荡反弹，早盘创新药、AI医疗等细分领域再度活跃，表现亮眼。截至发稿，港股通医 疗ETF富国（159506）盘中涨幅达3.89%，其成分股药明生物、时代天使涨超7%，微创机器人-B涨超 6%。此外，创新药ETF富国（159748）盘中涨幅达3.03%。 消息面上，国家药监局日前介绍，目前，我国医药产业规模位居全球第二位，在研创新药数目达到全球 30%左右。"十四五"以来，共批准387个儿童药品、147个罕见病药品上市，有效满足了重点人群的用药 需求。 ...

Core Viewpoint - The recent trading data indicates a modest activity in the Hong Kong Stock Connect Medical ETF managed by Fu Guo, with a slight net selling position observed over the last few days [1] Group 1: Financing Activity - On August 25, the Fu Guo Medical ETF received a financing buy amount of 0.18 billion, ranking 1906th in the two markets [1] - Over the last three trading days (August 21-25), the ETF received financing buy amounts of 0.22 billion, 0.22 billion, and 0.18 billion respectively [1] - The financing repayment amount on August 25 was 0.19 billion, resulting in a net selling of 1.13 million [1] Group 2: Short Selling Activity - On August 25, there were no shares sold short, resulting in a net short selling of 0.00 shares [1]

Core Viewpoint - The A-share market has been on the rise, with the Shanghai Composite Index reaching a nearly four-year high of 3688 points on August 13, and a total trading volume of 2.15 trillion yuan, indicating strong market momentum and investor sentiment [1] Fund Performance - As of August 11, among the top fund management companies with over 100 billion yuan in mixed fund management scale, Fortune Fund achieved an average return of 30.06%, ranking third [1] - Fortune Fund's stock funds have also performed exceptionally well, with an average return of 43.47% over the past year [1] - A total of 145 products under Fortune Fund have achieved returns exceeding 30% in the past year, with 73 products exceeding 50%, and 14 products achieving returns over 80% [2] Specific Fund Highlights - The best-performing fund is the Hong Kong Stock Connect Medical ETF managed by Tian Ximeng, with a return of 112.38% [2] - Other notable funds with returns exceeding 90% include Fortune Active Growth One Year, Fortune Hang Seng Medical ETF, and Fortune North China 50 [2] - The Fortune Optimized Enhanced Bond Fund, managed by Liu Xingwang, achieved a return of 41.97%, ranking high among peers [2] Net Asset Value Achievements - Nearly 50 active equity funds under Fortune Fund have reached historical net asset value highs as of August 13 [3] - Funds such as Fortune Active Growth One Year and Fortune Small Cap Selection have set new highs since their inception [3] Competitive Rankings - Six active equity funds from Fortune Fund rank first in their respective categories, with 24 funds in the top five [4] - The Fortune Medical Innovation Fund, managed by Zhao Wei and Wang Chao, ranked first among 46 similar funds, showcasing strong stock-picking capabilities [4] - The Fortune Consumption Selection Fund, managed by Zhou Wenbo, also ranked first in its category, benefiting from the new consumption investment trend [4] Continued Focus on Innovation - The Fortune New Materials and New Energy Fund, managed by Xu Zhixiang, ranks first among 24 similar funds, while the Fortune Craft Growth Fund achieved a return of 80.49%, ranking in the top three [5] - The Fortune New Vitality Fund, managed by Wu Dongdong, ranks second among 80 similar funds over the past year [6] Market Outlook - The A-share market remains active, with margin trading balances returning to 2 trillion yuan, further strengthening market bullish sentiment [6] - Fortune Fund aims to enhance its core investment capabilities and continue delivering excellent long-term performance for investors [6]

8月14日，沪深两融数据显示，港股通医疗ETF富国获融资买入额0.32亿元，居两市第1594位，当日融 资偿还额0.32亿元，净买入72.99万元。 最近三个交易日，12日-14日，港股通医疗ETF富国分别获融资买入0.15亿元、0.23亿元、0.32亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 本文源自：金融界 作者：智投君 ...

8月11日，沪深两融数据显示，港股通医疗ETF富国获融资买入额0.39亿元，居两市第1055位，当日融资 偿还额0.26亿元，净买入1276.59万元。 本文源自：金融界 作者：智投君 最近三个交易日，7日-11日，港股通医疗ETF富国分别获融资买入0.32亿元、0.23亿元、0.39亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Core Viewpoint - The recent trading data indicates a mixed performance for the Hong Kong Stock Connect Medical ETF, with a slight net selling position despite some inflows in financing purchases over the past three days [1] Group 1: Financing Activity - On August 6, the Hong Kong Stock Connect Medical ETF received a financing purchase amount of 0.26 billion, ranking 1152nd in the market [1] - The financing repayment amount on the same day was 0.27 billion, resulting in a net selling of 0.9949 million [1] - Over the last three trading days (August 4-6), the ETF saw financing purchases of 0.39 billion, 0.53 billion, and 0.26 billion respectively [1] Group 2: Short Selling Activity - On August 6, there were no shares sold short, resulting in a net short selling of 0.00 thousand shares [1]

最近三个交易日，1日-5日，港股通医疗ETF富国分别获融资买入0.45亿元、0.39亿元、0.53亿元。 8月5日，沪深两融数据显示，港股通医疗ETF富国获融资买入额0.53亿元，居两市第678位，当日融资 偿还额0.52亿元，净买入97.27万元。 本文源自：金融界 作者：智投君 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Core Viewpoint - The recent trading data indicates a steady interest in the Hong Kong Stock Connect Medical ETF managed by Fuguo, with notable financing activities over the past few days [1] Group 1: Financing Activities - On August 4, the Hong Kong Stock Connect Medical ETF by Fuguo recorded a financing buy amount of 0.39 billion yuan, ranking 911th in the market [1] - The financing repayment amount on the same day was 0.36 billion yuan, resulting in a net buy of 2.91 million yuan [1] - Over the last three trading days (July 31 to August 4), the ETF received financing buy amounts of 0.43 billion yuan, 0.45 billion yuan, and 0.39 billion yuan respectively [1] Group 2: Short Selling Activities - On August 4, there were no shares sold short, with a net short sale of 0.00 shares [1]

7月30日，沪深两融数据显示，港股通医疗ETF富国获融资买入额0.60亿元，居两市第665位，当日融资 偿还额0.67亿元，净卖出645.29万元。 最近三个交易日，28日-30日，港股通医疗ETF富国分别获融资买入0.46亿元、0.57亿元、0.60亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...